Halozyme suffers setback as FDA halts PhII cancer program for delivery safety concerns; Alkermes unleashes PhIII data for long-lasting Abilify version;

> Halozyme ($HALO) suffered a blow as the FDA halted its pancreatic cancer drug delivery system trial over safety concerns. The company voluntarily pulled back on its Phase II study late last week. Article | More from FierceBiotech

> Alkermes ($ALKS) finished its Phase III schizophrenia study for a long-lasting version of Abilify. The delivery method should help the company move into the drug market alone, whereas in the past it has partnered with Big Pharma to develop new products. Story

> Researchers at the University of Liverpool have developed nanoparticles that they say can increase the stability of HIV drugs. More

> Celsion ($CLSN) presented at the International Symposium on Therapeutic Ultrasound data supporting its ThermoDox heat-activated liposomal encapsulation of doxorubicin, which uses high intensity focused ultrasound to deliver the cancer drug. Release

Suggested Articles

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.

Bexson Biomedical and Stevanato Group teamed up to develop a ketamine pump that may help patients better manage pain at home.

Australia's University of New South Wales and Uka Tarsadia University in India will join forces to explore contact lenses for ocular drug delivery.